Revolution Medicines' GAAP loss for 3 months of 2022 was $57.647 million, up 55.1% from $37.176 million in the prior year. Revenue declined 25.2% to $7.578 million from $10.131 million a year earlier.
Revolution Medicines' GAAP loss for 3 months of 2022 was $57.647 million, up 55.1% from $37.176 million in the prior year. Revenue declined 25.2% to $7.578 million from $10.131 million a year earlier. 
ir.revmed.com
English (US) 